FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma

Journal of Nuclear Medicine

Volumn 41, Issue 6, 2000, Pages 1010-1015

  Alnafisi, Naheel S ^b   Driedger, Albert A ^a   Coates, Geoffrey ^b   Moote, Douglas J ^b   Raphael, Simon J ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

131I; FDG PET; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE; IODINE 131; THYROGLOBULIN;

ADULT; ALGORITHM; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADULT; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034130683     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Filesi M, Signore A, Ventroni G, Melacrinis F, Ronga G. Role of initial iodine-131 whole body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med. 1998;39:1542-1546.
2. Roelants V, Nayer P, Bouckaet A, Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:722-727.
3. Ronga G, Fiorentino A, Paserio E, et al. Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J Nucl Med. 1990;31:1766-1771.
4. Bomanji J, Britton K, Clarke S. Clinicians Guide to Nuclear Medicine, Oncology, 1st ed. London, UK: British Nuclear Medicine Society; 1995:24.
5. Maxon H, Smith H. Radioiodine-I-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19:685-718.
6. Pineda J, Lee T, Ain K, Reynolds J, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488-1492.
7. Unal S, Menda Y, Adalet I, et al. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. J Nucl Med. 1998;39:1897-1902.
8. Carril J, Quirce R, Serrano J, et al. Total-body scintigraphy with thallium-201 and iodine-131 in the follow up of differentiated thyroid cancer. J Nucl Med. 1997;38:686-692.
9. 131I in patients with metastatic thyroid carcinoma. Nucl Med Commun. 1997;18:3-9.
10. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmenter C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996;81:2541-2544.
11. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1987;28:910-914.
12. Feine U, Lietzenmayer R, Hanke J, Held J. Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-I-131-iodine uptake in thyroid cancer. J Nucl Med. 1996;37:1468-1472.
13. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342-1348.
14. Thyroid gland. In: Fleming ID, Cooper JS, Henson DE, et al., eds. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997:59-61.
15. Freitas J, Gross M, Ripley S, Shapiro B. Radionuclide diagnosis and therapy of thyroid cancer: current status report. Semin Nucl Med. 1985;15:106-131.
16. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23:312-319.
17. Hawk W, Hazard J. The many appearances of papillary carcinoma of thyroid: comparison with the common form of papillary carcinoma by DNA and morphometric analysis. Cleve Clin Q. 1976;43:207-215.
18. Moon D, Maddaahi J, Silverman D, Glaspy J, Phelps M, Hoh C. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431-435.
19. Sisson J, Ackermann R, Meyer M, Wahl R. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer; implications for diagnosis and therapy. J Clin Endocrinol Metab. 1993;77:1090-1094.
20. Sasaki M, Ichiya Y, Kuwabara Y, et al. An evaluation of FDG-PET in the detection and differentiation of thyroid tumors. Nucl Med Commun. 1997; 18:957-963.
21. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291-2302.